View Cart  

FDA Advisory Panel Unanimously Backs Novartis Cushing’s Disease Drug

A A
A 10-member FDA advisory panel voted unanimously Wednesday to recommend approval of Novartis’ Signifor for the treatment of Cushing’s disease. Signifor (pasireotide injection) should not be viewed as a “golden bullet,” but it may play a major role in the current management of the disease, Ellen Seely, Harvard Medical School, said.
Drug Industry Daily